Endometrioid endometrial cancers (EEC) frequently have multiple mutations at PTEN, PIK3CA, PIK3R1 and KRAS. The effects of the pan-class I PI3K inhibitor GDC-0941 and the mTORC1 inhibitor temsirolimus were examined on EEC cells with concurrent PIK3CA and PTEN mutations [209]. The gene discussed is KRAS; the disease is exstrophy-epispadias complex.